A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-Related fibrosis

Obesity Surgery

Volumn 21, Issue 4, 2011, Pages 431-439

  Younossi, Zobair M ^a,b,c   Page, Sandra ^b,c   Rafiq, Nila ^a,b   Birerdinc, Aybike ^b,c   Stepanova, Maria ^a   Hossain, Noreen ^a   Afendy, Arian ^a   Younoszai, Zahra ^a   Goodman, Zachary ^a   Baranova, Ancha ^b,c  

^a INOVA FAIRFAX HOSPITAL   (United States)

^b BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

Biomarkers; Hepatic fibrosis; NASH

Indexed keywords

ADIPONECTIN; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; GLUCOSE; HYALURONIC ACID; M30 PROTEIN; M65 PROTEIN; PROCOLLAGEN TYPE 3 AMINOPROPEPTIDE; RESISTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOKINES; ADULT; BIOLOGICAL MARKERS; BIOPSY; BLOOD GLUCOSE; FATTY LIVER; FEMALE; HUMANS; HYALURONIC ACID; KERATIN-18; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PEPTIDE FRAGMENTS; PROCOLLAGEN; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TISSUE INHIBITOR OF METALLOPROTEINASE-1;

EID: 79955764437     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-010-0204-1     Document Type: Article

References (39)

1. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology. 2003;37:917-23. (Pubitemid 36397405)
2. Rafiq N, Younossi ZM. Evaluation and management of nonalcoholic fatty liver disease. Clin Liver Dis. 2009;13:249-66.
3. Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology. 2002;35:746-52. (Pubitemid 34258367)
4. Younossi ZM, Gramlich T, Liu Y, et al. Non- alcoholic fatty liver: Assessment of variability in the pathologic interpretations. Mod Pathol. 1998;11(6):560-5. (Pubitemid 28280720)
5. Matteoni C, Younossi ZM, Gramlich T, et al. A non-alcoholic fatty liver disease: A spectrum of clinical and pathologic severity. Gastroenterology. 1999;116:1413-9. (Pubitemid 29258890)
6. Rafiq N, Bai CH, Fang Y, et al. Long-term follow-up of patients with non-alcoholic fatty liver. Clini Gastro Hepatol. 2009;7 (2):234-8.
7. Ekstedt M et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;44:865.
8. Rosenberg WM, Voelker M, Thiel R, European Liver Fibrosis Group, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology. 2004;127(6):1704-13. (Pubitemid 39575849)
9. Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. (Pubitemid 46631552)
10. Guha IN, Parkes J, Roderick P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2009;47(2):455-60. (Pubitemid 351280713)
11. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26. (Pubitemid 36919874)
12. Cales P, Laine F, Boursier J, Deugnier Y, Moal V, Oberti F, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD J Hepatol. 2009;50:165-73.
13. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg. 2008;18(11):1430-7.
14. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44(1):27-33. (Pubitemid 44049136)
15. Baranova A, Younossi ZM. The future is around the corner: Noninvasive diagnosis of the progressive nonalcoholic steatohepatitis. Hepatology. 2008;47(2):373-5. (Pubitemid 351280704)
16. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, Goodman Z, Younossi Z. Independent predictors of fibrosis in patients with non-alcoholic fatty liver disease. Clin Gastro Hepatol 2009;7(11):1224-9.
17. Bondini S, Kleiner DE, Goodman Z, et al. Pathologic assessment of non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:17-23. (Pubitemid 46829967)
18. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000;32:477-81.
19. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005;128:1898-906. (Pubitemid 40824701)
20. Miele L, Forgione A, Gasbarrini G, et al. Noninvasive assessment of fibrosis in non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Transl Res. 2007;149:114-25. (Pubitemid 46275574)
21. Ratziu V, Giral P, Munteanu M, et al. Screening for liver disease using non-invasive biomarkers (FibroTest, SteatoTest and NashTest) in patients with hyperlipidaemia. Aliment Pharmacol Ther. 2007;25:207-18. (Pubitemid 46046377)
22. Wieckowska A, Zein NN, Yerian LM, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatology. 2006;44:27-33. (Pubitemid 44049136)
23. Chitturi S, Farell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001;21(1):27-41. (Pubitemid 32240484)
24. Edmison J, McCullough AJ. Pathogenesis of non-alcoholic steatohepatitis: Human data. Clinics in Liver Disease. 2007;11 (1):75-104. (Pubitemid 46829977)
25. London R, George J. Pathogenesis of NASH: Animal models. Clin Liver Dis. 2007;11(1):55-74. (Pubitemid 46829974)
26. Nugent C, Younossi ZM. Evaluation and management of obesityrelated non-alcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;14(No. 8):432-41. (Pubitemid 47208893)
27. Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liver disease: A global perspective. Semin Liver Dis. 2008;28(4):339-50.
28. Saadeh S, Younossi ZM, Remer EM, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;123:745-150.
29. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of NASH. Clin Liver Dis. 2007;11(1):37-54. (Pubitemid 46829975)
30. Nguyen-Khac E, Capron D. Noninvasive diagnosis of liver fibrosis by ultrasonic transient elastography (Fibroscan). Eur J Gastroenterol Hepatol. 2006;18:1321-5. (Pubitemid 44737064)
31. Ong J, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in obese patients. Obesity Surgery. 2005;15(3):310-5. (Pubitemid 40463594)
32. Baranova A, Gowder SJ, Schlauch K, et al. Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance. Obes Surg. 2006;16:1118-25. (Pubitemid 44433145)
33. Younossi ZM, Gorreta F, Ong JP, et al. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760-71. (Pubitemid 41038658)
34. Younossi ZM, Baranova A, Ziegler K, et al. A genomic and proteomic of study of the spectrum of non-alcoholic fatty liver disease. Hepatology. 2005;41(3):665-74. (Pubitemid 41233660)
35. Calvert VS, Collantes R, Elariny H, et al. A systems biology approach to non alcoholic fatty liver disease pathogenesis using multiplexed cell signaling analysis. Hepatology. 2007;46 (1):166-72.
36. Baranova A, Liotta L, Petricoin E, et al. The role of genomics and proteomics technologies in studying non-alcoholic fatty liver disease. Clin Liver Dis. 2007;11:209-20. (Pubitemid 46829968)
37. Itagaki T, Shimizu I, Cheng X, et al. Opposing effects of oestradiol and progesterone on intracellular pathways and activation processes in the oxidative stress induced activation of cultured rat hepatic stellate cells. Gut. 2005;54:1782-9. (Pubitemid 41697679)
38. Shimizu I, Kohno N, Tamaki K, et al. Female hepatology: Favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol. 2007;13:4295-305. (Pubitemid 47377132)
39. Shimizu I, Ito S. Protection of estrogens against the progression of chronic liver disease. Hepatol Res. 2007;37:239-47. (Pubitemid 46505837)